Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04747834
Other study ID # MICOR-304-101
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 6, 2021
Est. completion date December 2025

Study information

Verified date January 2024
Source Carl Zeiss Meditec, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate the clinical outcomes of the use of low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion in subjects undergoing routine cataract surgery.


Description:

Up to 300 eyes at up to 5 investigational sites will be enrolled in one of the two cohorts of this clinical investigation - up to 50 eyes in Cohort 1 and up to 50 eyes in Cohort 2. Only one eye per subject will be enrolled into the study. This is multicenter, multi-cohort, prospective clinical study designed to provide longitudinal, observational, non-comparative clinical outcome data for mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion. Participants who meet the inclusion and exclusion will be asked to enroll in the study. The investigator or designee will explain the study purpose, procedures and responsibilities to the potential participant and provide sufficient opportunity to ask questions, while allowing adequate time for consideration of the information provided. Upon participant confirmation of interest, written informed consent will be obtained and the subject will be enrolled in the study. One copy of the informed consent document (ICD) will be retained with the subject's medical records and one copy will be provided to the subject. Study subjects will be stratified into two Cohorts. Cohort 1 is comprised of eyes with mild-to- moderate cataracts only (Grade 1 to 2). Cohort 2 is comprised of eyes with moderate to more dense cataracts only (Grade 2+ to 3+). Subjects will be seen at the screening visit, intraoperative visit, and at post-operative days 1, 7, and 30.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 300
Est. completion date December 2025
Est. primary completion date November 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Able to understand study requirements, willing to follow study instructions and willing to return for required study follow-up visits 2. Willing and able to understand and complete the informed consent document 3. Subjects with a cataract grade of 1 to 3+ and are scheduled to undergo cataract surgery 4. Subjects = 18 years of age 5. Clear intraocular media, other than cataract Exclusion Criteria: 1. Polar cataracts 2. Zonular instability 3. History of dry eye treatments/devices and or dry eye medications other than artificial tears. 4. Concurrent participation or participation in any clinical trial up to 30 days prior to preoperative visit 5. Subjects that are pregnant, lactating or planning to become pregnant during the course of the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MICOR-304
The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.

Locations

Country Name City State
United States Chu Vision Institute Bloomington Minnesota
United States Argus Research at Cape Coral Eye Center Cape Coral Florida
United States Young H. Choi Eye Surgery Center Vestavia Hills Alabama

Sponsors (2)

Lead Sponsor Collaborator
Carl Zeiss Meditec, Inc. Carl Zeiss Meditec Cataract Technology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total lens removal time Total lens removal time is defined in two phases:
The beginning time starts when the surgeon enters the eye with the MICOR-304 to start the lens removal process and completing when the surgeon finishes the nucleus lens removal with the MICOR-304 before changing over to irrigation and aspiration.
o The second phase of lens removal time is the irrigation and aspiration stage for cortex removal which starts when the irrigation and aspiration tip enters the eye and completion time is when the cortex is removed.
The total lens removal time as defined above is recorded in minutes and seconds.
Assessed during the surgical procedure.
Primary Amount of irrigation solution fluid volume used during the surgical procedure Total irrigation solution volume will be recorded using the indicators on the bag which will have labels that have pre-defined markers to indicate milliliters (ml) of volume of irrigation solution used for the surgical procedure. Assessed during the surgical procedure.
Secondary Uncorrected Visual Acuity Assessment of Uncorrected Visual Acuity. Postoperative days 1, 7, and 30.
Secondary Change in corneal thickness Assessment in change in corneal thickness from baseline through end of study. Baseline through 30 days postoperative.
Secondary Rate of occurrence of intraoperative and postoperative adverse events Assessment of intraoperative and postoperative adverse events. From study enrollment through study completion at 1 month postoperative.
Secondary Corneal Edema Corneal edema will be assessed as the following: 0=None, 1+=Mild, 2+=Moderate and 3+=Severe assessed via slit-lamp. Pre-operative, 1-day, 1-week and 1-month postoperative study completion.
Secondary Corneal Cells Corneal cells will be assessed as the following: 0=>1 cell, 0.5+=1-5 cells, 1+=6-15 cells, 2+=16-25 cells, 3+=26-50 cells and 4+=>50 cells assessed via slit-lamp. Pre-operative, 1-day, 1-week and 1-month postoperative study completion.
Secondary Anterior Chamber Flare Anterior chamber flare will be assessed as the following: 0-None, 1+=Faint, 2+=Moderate, (iris and lens details clear), 3+=Marked (iris and lens details hazy), 4+=Intense fibrin or plastic aqueous assessed via slit-lamp. Pre-operative, 1-day, 1-week and 1-month postoperative study completion.
Secondary Posterior Capsule Opacification Posterior capsule opacification will be assessed as the following: none, minimal, mild, moderate and severe assessed via slit-lamp. Pre-operative, 1-day, 1-week and 1-month postoperative study completion.
Secondary Corneal Staining Erosion Corneal staining erosion will be assessed as the following: 0=None, 1+=Mild, 2+=Moderate and 3=Severe assessed via slit-lamp. Pre-operative, 1-day, 1-week and 1-month postoperative study completion.
Secondary Disc Appearance Disc appearance is assessed as normal and abnormal with free text to specify if abnormal, assessed via dilated fundus examination. Pre-operative and 1-month postoperative study completion.
Secondary Macula Macula is assessed as normal and abnormal with free text to specify if abnormal, assessed via dilated fundus examination. Pre-operative and 1-month postoperative study completion.
Secondary Vessels Vessels are assessed as normal and abnormal with free text to specify if abnormal, assessed via dilated fundus examination. Pre-operative and 1-month postoperative study completion.
Secondary Periphery Periphery is assessed as normal and abnormal with free text to specify if abnormal, assessed via dilated fundus examination. Pre-operative and 1-month postoperative study completion.
Secondary Total Surgical Procedure Time Total Surgical Procedure Time time is defined as the beginning time when the surgeon makes the first incision in the eye and completion time is when the eye speculum is removed at the end of the procedure. Total surgical procedure time is recorded in minutes and seconds. Assessed during the surgical procedure.
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A